SAB Biotherapeutics, Inc. (SABS) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
SAB Biotherapeutics (SABS) synthesizes antibodies independently but delegates the final testing stages to external contractors, while the platform's high scalability ensures the rapid launch of new drugs and significant revenue. This chart on GURU.Markets reflects an EV/EBITDA price trend of 0.00. The US-based localization of development and the specifics of the medical field minimize political threats, guaranteeing stable technological growth.
sabbiotherapeutics.com - analytical breakdowns and key metrics (SABS)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity SAB Biotherapeutics|SABS - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital SAB Biotherapeutics, Inc.|SABS - Company Cumulative Debt|Debt to Book Capitalization Ratio SAB Biotherapeutics Inc|SABS - Long-Term Debt Volume|Company Short-Term Debts SAB Biotherapeutics|Quick Ratio sabbiotherapeutics.com
- business earnings and investment ratios data:
SABS - Company Net Income|Future Profit SAB Biotherapeutics|SABS - Company Value to Net Income|Forward P/E Multiple SAB Biotherapeutics|SABS - Price/Earnings to Growth Ratio|EV/EBITDA Multiple SAB Biotherapeutics Inc|SABS - Operating income before deduction of amortization|Earnings per share for the last twelve months SAB Biotherapeutics|SABS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months sabbiotherapeutics.com|SABS - Net earnings per one share growth for the current year|Earnings growth forecast for next year SAB Biotherapeutics
Initial company analysis:SABS (SAB Biotherapeutics, Inc)
For an investor assessing the market status of SAB Biotherapeutics (SABS), the balance between business value and operational efficiency is key. The current value of 0.00 reflects the company's enterprise value relative to EBITDA; by analyzing the historical EV/EBITDA multiples of SAB Biotherapeutics, one can evaluate the funding stability for the development of immunotherapy drugs, where a declining multiple signals an undervaluation of assets while volatility risks persist.
Analysis of competing companies
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Dianthus Corp DNTH|PHVS: EV/EBITDA Multiple|AbCellera (ABCL) - EV/EBITDA Multiple|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|Enterprise Value to EBITDA Ratio PHAR (Pharming)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Immunome - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Gossamer Bio Inc GOSS|KalVista Pharmaceuticals Inc (KALV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Septerna Pharma (SEPN)|Enterprise Value to EBITDA Ratio PVLA|SVRA (savarapharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXS (Astria Pharma)|enGene Corp (ENGN) - Company Value to EBITDA|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (Aerovate Therapeutics Inc)|ACRS: EV/EBITDA Multiple|Kyverna Therapeutics Inc. (KYTX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|Cabaletta Bio Inc - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple VTYX|THTX - Company Value to EBITDA|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Enterprise Value to EBITDA Ratio|Climb Bio, Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ZURA: EV/EBITDA Multiple|ATYR - Total Company Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ikena Oncology, Inc. (IMA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|Total Company Value to Operating Income Before Depreciation Ratio equilliumbio.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Connect Biopharma Holdings Limited CNTB|Total Company Value to Operating Income Before Depreciation Ratio Immunic Therapeutics (IMUX)|Atara Biotherapeutics Inc - EV/EBITDA Multiple|IFRX - EV/EBITDA Multiple|XFOR: EV/EBITDA Multiple|ACET (Adicet Bio, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|inmunebio.com (INMB) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Barinthus Biotherapeutics plc (BRNS)|KZR: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|Business Value to Operating Income Before Depreciation ENLV|Q32 Bio Corp - EV/EBITDA Multiple|GOVX - EV/EBITDA Multiple|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|iBio Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Carisma Therapeutics Inc|Enterprise Value to EBITDA Ratio XTL Bio (XTLB)|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AIM|Aditxt Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to EBITDA Ratio SCNI (Scinai)|EV/EBITDA Multiple calcimedica.com (CALI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK: Enterprise Value to Operating Income Before Depreciation|HOOKIPA - EV/EBITDA Multiple|Company Value to EBITDA IGM Biosciences, Inc.|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OCEA - Total Company Value to Operating Income Before Depreciation Ratio|TCBP (TC Biopharm) - EV/EBITDA Multiple|EV/EBITDA Multiple thirdharmonicbio.com
